This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Roche Bid Could Alter Pharma's DNA

Updated from 10:30 a.m. EDT

Roche's $89-a-share offer for Genentech (DNA) is notable not just for the fact that it could mark the end of an era for the best biotech in the history of the industry, but for the repercussions it could potentially have on the rest of the sector.

First things first: Is the offer too low? The market seems to think so, with shares of Genentech trading up 14.7% to $93.88. I agree. I believe Roche has to up the bid.

On its conference call this morning, Roche sounded very firm with the offer, calling it "fair and generous" several times. Roche insisted that a takeout premium isn't justified in this case because the company already controls Genentech with its current 56% stake. In essence, Roche isn't acquiring Genentech as much as taking the company private.

The $89-a-share offer represents a 9% premium to Genentech stock's closing price Friday and a 19% one-month premium, but is it a fair offer when you factor in the multibillion-dollar commercial opportunity for Avastin in adjuvant colon cancer?

No way. UBS says a successful outcome for the Avastin adjuvant colon cancer trial could be worth $20 a share to Genentech's current stock price. (The next interim analysis from the study is due in the fourth quarter.)

JP Morgan biotech analyst Geoff Meacham, in an early-morning note to clients, agrees that the offer is low and that this may just be the start of the negotiating process, with a higher bid to come.

Lehman Brothers: Roche's offer is too low. The firm raised its Genentech price target to $105 a share Monday morning based on a reasonable counter proposal of $120 a share by Genentech's independent directors.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs